Additionally, our investigation revealed that EGR1 augmented the sensitivity of HCC cells and xenograft tumors to sorafenib. A mechanistic analysis, employing transcriptome sequencing, revealed that EGR1 engaged with the promoter region of phosphofructokinase-1, liver type (PFKL), resulting in the transcriptional suppression of PFKL expression and consequent inhibition of the glycolysis pathway. The gene discussed is EGR1; the disease is hepatocellular carcinoma.